Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Synthetic Vaccines in TNBC
NCT06195618Phase 1Not yet recruiting
- Sponsor
- Universidad Nacional de Colombia
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in triple-negative breast cancer (TNBC), sponsored by Universidad Nacional de Colombia. Primary endpoint: Number of adverse effects at 3 months. Planned start Aug 2025; status: not yet recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06195618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195618.